BCM
PLX icon

Burrage Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Burrage Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,125,585
Closed -$9.48M – 26
2021
Q1 		$9.48M Sell
2,125,585
-344,747
-14% -$1.61M 7.68% 1
2020
Q4 		$8.97M Buy
+2,470,332
New +$8.85M 6.83% 5

Other funds holding PLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Burrage Capital Management's PLX Position: Q2 2021 in Review

Burrage Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2021, closing a stake of 2,125,585 shares — an estimated $9.48M sold.

Burrage Capital Management first reported a position in PLX in Q4 2020 and held it in 2 quarters. The position peaked at $9.48M in Q1 2021. 33 funds tracked by Wall St. Rank hold PLX as of Q2 2021.

  • Burrage Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2021 after selling out during the quarter.
  • Burrage Capital Management sold 2,125,585 Protalix BioTherapeutics shares in Q2 2021, an estimated $9.48M.
  • Burrage Capital Management first reported a position in Protalix BioTherapeutics in Q4 2020 and held it in 2 quarters.
  • Burrage Capital Management's Protalix BioTherapeutics position peaked at $9.48M in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2021.

Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.